Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Firefly Neuroscience (AIFF) Asset Writedowns and Impairment (2016 - 2025)

Firefly Neuroscience has reported Asset Writedowns and Impairment over the past 5 years, most recently at $99000.0 for Q4 2025.

  • Quarterly results put Asset Writedowns and Impairment at $99000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $251000.0 (changed N/A YoY), and the annual figure for FY2025 was $251000.0, down 71.28%.
  • Asset Writedowns and Impairment for Q4 2025 was $99000.0 at Firefly Neuroscience, down from $152000.0 in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for AIFF hit a ceiling of $152000.0 in Q3 2025 and a floor of $99000.0 in Q4 2025.